Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an update.
Grand Pharmaceutical Group Limited has entered into a sales agreement with Yuanda Jiufu, a subsidiary of its controlling shareholder, China Grand Enterprises. This agreement involves the sale of raw materials for the production of amino acid and other pharmaceutical products. The transaction is categorized as a continuing connected transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but exempting the need for a circular or shareholder approval. This move is expected to strengthen the company’s operational ties within its group, potentially enhancing its market position in the pharmaceutical sector.
The most recent analyst rating on (HK:0512) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated company listed on the Hong Kong Stock Exchange. It operates in the pharmaceutical industry, focusing on the production and sale of amino acid products and other pharmaceutical products. The company is primarily controlled by China Grand Enterprises Incorporation, which holds a significant share of its issued capital.
Average Trading Volume: 26,071,971
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.97B
Learn more about 0512 stock on TipRanks’ Stock Analysis page.